Amgen to present updated data on Nplate at the 2009 ASH meeting

October 07, 2015

Abstract No. 1769 (Embargoed until Dec. 5, 5:30pm): "Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine"Abstract No. 1770 (Embargoed until Dec. 5, 5:30pm): "Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide"Abstract No. 2765 (Embargoed until Dec. 6, 6:00pm): "An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)"

Aranesp? (darbepoetin alfa)

Researchers will also present efficacy and safety data from an independent investigator-led study that is part of the Aranesp Pharmacovigilance program.

Abstract No. 1701 (Embargoed until Dec. 5, 5:30pm): "Efficacy and Safety of Prophylactic Use of Darbepoetin Alfa in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results of the Interim Analysis of the LNH03-6B GELA Study"

SOURCE Amgen Inc.